On October 21, Novo Nordisk announced positive news on the cardiovascular benefits of its oral glucagon-like peptide-1 receptor (GLP-1R) agonist, Rybelsus, which is currently approved for type 2 ...

Oral semaglutide, sold as Rybelsus, reduced the risk of a group of cardiovascular events by 14% compared with placebo in certain patients with Type 2 diabetes in a late-stage study, Novo said Monday.

It’s called Rybelsus. How does oral semaglutide work compared to the injectable version? You may be curious if one form of semaglutide is more effective than the other or if one type causes more ...

Rybelsus is an oral glucagon-like peptide-1 (GLP-1) agonist and sibling medication to Ozempic and Wegovy. Per a phase 3 trial, Rybelsus was found to reduce cardiovascular risk among patients with ...

Bernstein said Novo Nordisk’s (NVO) recently released SOUL study results for Rybelsus in the reduction of major cardiovascular events in diabetic patients were modest and not as robust as ...

Rybelsus is an oral form of semaglutide, the active ingredient in the company’s blockbuster Ozempic and Wegovy diabetes and weight-loss drugs, and was tested in the trial on diabetic patients ...

Novo Nordisk plans to seek regulatory approval for Rybelsus label expansion by late 2024 or early 2025. On Monday, Novo Nordisk A/S NVO released the headline results from the SOUL Phase 3 ...

Oral semaglutide (Rybelsus) lowered the risk for major adverse cardiovascular events (MACEs) by a significant 14% compared with placebo, Novo Nordisk announced. The topline results met the primary ...

The drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, non-fatal heart attack and stroke, by 14% compared to placebo, meeting the main goal of the trial.

According to a report by news agency Reuters, the drug, Rybelsus, helped reduce the risk of these events, including cardiovascular death, non-fatal heart attack and stroke, by 14% compared to ...